Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
AbbVie (4AB) Stock Price & Analysis
10 Followers
4AB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€115.42 - €167.35
Previous Close€158.46
Volume1.00
Average Volume (3M)712.00
Market Cap
€280.28B
Enterprise Value€323.80B
Total Cash (Recent Filing)$12.82B
Total Debt (Recent Filing)$59.38B
Price to Earnings (P/E)63.0
Beta0.02
Next Earnings
Apr 26, 2024EPS Estimate
€2.11Last Dividend Ex-Date
Apr 12, 2024Dividend Yield3.53%
Share Statistics
EPS (TTM)2.51
Shares Outstanding1,766,473,359
10 Day Avg. Volume744
30 Day Avg. Volume712
Standard Deviation0.07
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-3.86
Price to Sales (P/S)5.12
Price to Cash Flow (P/CF)15.80
P/FCF Ratio15.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.96
Enterprise Value/Gross Profit9.55
Enterprise Value/Ebitda20.21
Forecast
1Y Price Target
€167.89Price Target Upside8.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
AbbVie News
PremiumPre-Earnings
Is ABBV a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHigh return on equity at 34.90% signals strong financial performance.
Product GrowthRinvoq and Skyrizi are showing robust prescription growth, which could lead to stronger ex-US sales.
Strategic PartnershipsAlvotech announced a long-term agreement to enhance access to Adalimumab-ryvk in the U.S. market.
Bears Say
Earnings PressureAbbVie lowered 1Q24 EPS guidance which may indicate potential short-term earnings pressure.
Increased CompetitionHeme-onc sales could slightly miss due to competition, with Imbruvica and Venclexta demand softer year over year.
Product Sales DeclineAesthetics may be a source of weakness, with Botox sales possibly surprising to the downside by $30M versus consensus estimates.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.27% Insiders
21.66% Mutual Funds
21.82% Other Institutional Investors
56.26% Public Companies and
Individual Investors
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €115.42 and its highest was €167.35 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Apr 26, 2024 which is yesterday.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Feb 02, 2024. The company reported €2.606 earnings per share for the quarter, missing the consensus estimate of €2.608 by -€0.003.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.45 which represents an annual dividend yield of 3.53%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is €2.11.
How many shares outstanding does AbbVie have?
AbbVie has 1,770,647,000 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.606 in its last earnings report, missing expectations of €2.608. Following the earnings report the stock price went up 2.68%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 208M.
---
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€167.89 (8.15% Upside)
€167.89 (8.15% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 94%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $81.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.56%
12-Months-Change
Fundamentals
Return on Equity
34.90%
Trailing 12-Months
Asset Growth
-2.95%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
4AB Company Deck
---
4AB Earnings Call
Q4 2024
0:00 / 0:00
---
4AB Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
4AB Stock 12 Months Forecast
Average Price Target
€167.89
▲(8.15% Upside)
Technical Analysis
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
32/36 ratings generated profit
1 Year Average Return
+21.87%
reiterated a buy rating 6 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +21.87% per trade.
---